Portugal
Oncology, drugs take years to reach the patient.
Publication: Observador - Últimas
Author: Agência Lusa
Source published: 29/09/2026, 12:38:23 UTC
Briefing created: 30/09/2026, 00:41:24 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/09/2026, 12:46:25 UTC.
Briefings
Between 2020 and 2025, 57 oncology-related drug applications were submitted to the Infarmed, resulting in 26 new drug approvals and 37 early access programs. The evidence indicates a significant gap between submission and approval, with many processes taking years to reach patients. The data reflects a snapshot of the period from 2020 to 2025, and the specific timeline for individual drug approvals remains unclear.
Key points
- Between 2020 and 2025, 57 oncology-related drug applications were submitted to the Infarmed, resulting in 26 new drug approvals and 37 early access programs.
- Many drug approval processes reportedly took years to reach patients, indicating a significant delay in the translation of research into clinical use.
Context and limitations
The evidence covers the period from 2020 to 2025 and includes 57 total submissions. Specific dates for individual drug approvals are not provided, and the exact timeline for each process remains unclear.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 30/09/2026, 00:41:24 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeihwatxrye7cjiurf7fs3jls2e3ef6m76dirty5qfrtwtcbuq3qlcy